Resist Acineto rapid immunological test for the detection of acquired carbapenemase producers among Acinetobacter spp.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 28 04 2023
revised: 13 07 2023
accepted: 24 07 2023
medline: 4 10 2023
pubmed: 2 9 2023
entrez: 1 9 2023
Statut: ppublish

Résumé

The Resist Acineto from Coris Bioconcept is a novel immunochromatographic test for detection of the major acquired carbapenemases (OXA-23, OXA-40, OXA-58, and NDM) identified in Acinetobacter spp. This rapid and easy-to-perform test showed an excellent specificity and sensitivity, with positive and negatives predictive values of 100% in both cases.

Identifiants

pubmed: 37657230
pii: S0732-8893(23)00153-0
doi: 10.1016/j.diagmicrobio.2023.116043
pii:
doi:

Substances chimiques

carbapenemase EC 3.5.2.6
beta-Lactamases EC 3.5.2.6
Bacterial Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116043

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest PN and LP are inventors of the Rapid Acineto Carba NP test aimed to identify biochemically carbapenemase production in Acinetobacter baumannii.

Auteurs

Maxime Bouvier (M)

National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg and Institute for Microbiology, Fribourg, Switzerland; Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.

Auriane Kerbol (A)

National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg and Institute for Microbiology, Fribourg, Switzerland.

Jacqueline Findlay (J)

Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.

Samanta Freire (S)

Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.

Laurent Poirel (L)

National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg and Institute for Microbiology, Fribourg, Switzerland; Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.

Patrice Nordmann (P)

National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg and Institute for Microbiology, Fribourg, Switzerland; Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; University of Lausanne and University Hospital Centre, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH